Chief Financial Officer
Arcutis Biotherapeutics, Inc.
Scott Burrows has served as the chief financial officer of Arcutis Biotherapeutics for the past two years and as vice president of finance for the two years prior. Arcutis, founded in 2016, is a biopharmaceutical company that focuses on meaningful advances in the treatment of immune mediated skin disease.
Before his time at Arcutis, Burrows has accumulated a breadth of financial experience from a large pharmaceutical company spanning over 15 years where he was able to rotate through various internal facing roles and climb the decision-making ladder. His incremental experience of capital finance, FP&A, commercial finance, treasury, and investor relations allows for his holistic financial analysis and “full picture” mindset to help ensure Arcutis makes sound investment decisions.
In an early-stage commercial company such as Arcutis, the CFO’s role has a large range of responsibilities to ensure that the company is well financed to support its clinical development program and its path to commercialization. Under Burrows’ leadership, Arcutis has been able to conduct a successful initial public offering in January 2020 at a price of $17 per share, raise additional financing in venture capital before going public amounting to more than $160 million, with $94.5 million in 2019 alone. Since Arcutis’ IPO, Burrows and his team have secured over $220 million in 2020 through a public offering of common stock, secured $225 million in non-dilutive debt financing in 2021, and most recently raised an additional $173 million through a public offering of common stock in August 2022.